Recombinant Human Beta-NGF Expression in E. coli
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing human β-NGF are limited by the inability to isolate it in pure form and the challenges of expressing it as a mature polypeptide without fused homologous proteins, which can lead to immunogenic responses and contamination with other mammalian proteins.
Innovation Solution
The development of recombinant DNA expression vectors and host cells, such as E. coli, to express the β-subunit of human NGF as a mature polypeptide, free from fused proteins and other mammalian contaminants, using specific gene sequences and promoters to ensure accurate expression and purification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If extraction methods are used to obtain NGF from mouse salivary glands, then NGF can be obtained, but it is contaminated with other mammalian proteins and cannot be isolated in pure form
Solution Approach 1:
The NGF gene is segmented into specific coding sequences that are inserted into bacterial plasmids, allowing selective expression of only the desired NGF protein without other mammalian contaminants. This genetic segmentation enables pure NGF production through recombinant bacteria.
Solution Approach 2:
Bacterial cells serve as intermediary hosts that express human NGF protein through recombinant DNA technology. These bacteria act as living factories that produce pure NGF without the contamination issues inherent in mammalian extraction methods.
2Ease of manufacture
If fused homologous proteins are used to express β-NGF, then expression can be achieved, but immunogenic responses may occur
Solution Approach 1:
The invention extracts and expresses only the essential β-subunit coding sequence of NGF without including fused homologous proteins. This selective extraction of the functional coding region eliminates immunogenic components while maintaining NGF's therapeutic activity.
Solution Approach 2:
The invention changes the expression parameters by using specific bacterial promoters and ribosome binding sites optimized for E. coli expression systems, enabling efficient production of pure β-NGF without requiring fusion proteins that would trigger immune responses.
Data Source
AI summary
The β-subunit of human nerve growth factor (βNGF) is prepared in essentially pure form in commercially useful quantities using recombinant DNA technology. The nucleotide sequence and vectors encoding human βNGF and host cells transformed with the vectors are also provided. The βNGF which the invention provides is useful, for example, in treating nerve damage.